Parnassus Investments highlighted Boston Scientific as a stock poised to benefit from Trump-era tariffs.
1 report, 0 independent
Updated Jun 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Parnassus Investments highlighted Boston Scientific as a stock poised to benefit from Trump-era tariffs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
Related events
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
- Trump's tariffs spooked markets, specifically impacting MSCI.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
Coverage
Newest first; wire copies grouped- Unknown outlet